A discussion on therapeutic development in FSHD.
Dates and Times
Start: 4/26/2019 8:00 AM
End: 4/26/2019 9:00 AM
1. Understanding the prevalence of FSHD, its basic pattern of muscle involvement and spectrum of disease severity
2. Understanding the core mechanism of FSHD, the epigenetic turning on of a gene not normally expressed in somatic tissue.
3. Understanding the challenges of designing clinical trials in a rare disease with variable progression and an elusive causal protein
HSC level 3, lecture hall 6
Stony Brook Medicine
Stony Brook, NY 11794
The School of Medicine, State University of New York at Stony Brook, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The School of Medicine, State University of New York at Stony Brook designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s) ™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.